The analysis into the Chinese Prostate Cancer Genome and Epigenome Atlas (CPGEA) cohort revealed FOXA1 mutation in 41% of localized prostate tumours, a rate significantly higher than Western cohorts (Li et al. 2020). This evidence concerns the gene FOXA1 and Familial prostate cancer.